Recombinant Mouse CTLA-4 protein (His Tag)

ED50

0.1-0.4 μg/mL

Species

Mouse

Purity

>95 %, SDS-PAGE

GeneID

12477

Accession

NP_033973

Cat No : Eg0632

Print datasheet

Synonyms

CD152, CELIAC3, CTLA4, CTLA-4, IDDM12



Technical Specifications

Purity >95 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED50 for this effect is 0.1-0.4 µg/mL when stimulated with 1 µg/mL Recombinant Human CD80 in the presence of PHA.
Source HEK293-derived Mouse CTLA-4 protein Glu36-Phe162 (Accession# NP_033973) with His tag at the C-terminus.
Predicted Molecular Mass 14.8 kDa
SDS-PAGE 18-23 kDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CTLA-4, also known as CD152, belonging to the immunoglobulin superfamily, is primarily found on activated T cells and regulatory T cells (Tregs). CTLA-4 is closely related to the T-cell costimulatory CD28, and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4 acts as a negative regulatory molecule of T-cell responses. Besides the full-length transmembrane form, CTLA-4 also exists in a truncated soluble form (sCTLA-4).

References:

1. Brunet JF, et al. (1987) Nature. 328(6127):267-70. 2. Harper K, et al. (1991) J Immunol. 147(3):1037-44. 3. McCoy KD, et al. (1999) Immunol Cell Biol. 77(1):1-10. 4. Oaks MK, et al. (2000) Cell Immunol. 201(2):144-53.